Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: Proceedings from the Second Workshop on Pediatric Formulations

Clinical Therapeutics

Volumn 34, Issue 11, 2012, Pages

  Giacoia, George P ^a   Taylor Zapata, Perdita ^a   Zajicek, Anne ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOPHILE; NANOTUBE;

ARTICLE; BIODEGRADABILITY; CHILD; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDUSTRY; FLAVOR; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CENTER; HUMAN; IN VITRO STUDY; INHALATIONAL DRUG ADMINISTRATION; INTRAOCULAR DRUG ADMINISTRATION; IONTOPHORESIS; LOW LEVEL LASER THERAPY; MASKING; NANOEMULSION; NANOTECHNOLOGY; PATENT; PREDICTIVE VALUE; RETROLENTAL FIBROPLASIA; SKIN TEMPERATURE; TASTE; TELECONFERENCE; TOPICAL DRUG ADMINISTRATION; WORKSHOP;

ADOLESCENT; AGE FACTORS; CHEMISTRY, PHARMACEUTICAL; CHILD; CHILD, PRESCHOOL; CONSENSUS; DOSAGE FORMS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; FLAVORING AGENTS; HUMANS; INFANT; INFANT, NEWBORN; NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT (U.S.); PEDIATRICS; PHARMACEUTICAL PREPARATIONS; TASTE; TECHNOLOGY, PHARMACEUTICAL; TERMINOLOGY AS TOPIC; UNITED STATES;

EID: 84869016756     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.09.013     Document Type: Article

References (30)

1. Best Pharmaceuticals for Children Act January 4, 2002, (Public Law No. 107-109). http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm049876.htm.
2. Best Pharmaceuticals for Children Act and Pediatric Research Equity Act, 2007. http://www.aap.org/en-us/advocacy-and-policy/federal-advocacy/Documents/bpcapreasidexside.pdf.
3. Giacoia G.P., Taylor-Zapata P., Mattison D. Need for appropriate formulations for children: the Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulations Initiative. Int J Pharm Comp 2007, 11:220-225.
4. Giacoia G.P., Taylor-Zapata P., Mattison D. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation Initiative: selected reports from working groups. Clin Ther 2008, 30:2097-2101.
5. Kulo A., de Hoon J.N., Allegaert K. The propylene glycol research project to illustrate the feasibility and difficulties to study toxicokinetics in neonates. Int J Pharm 2012, 435:112-114.
6. Salunke S., Giacoia G.P., Tuleu C. The STEP (Safety and Toxicity of Excipients for Paediatrics) Database Part 1: A Need Assessment Study. Int J Pharm 2012, 435:101-111.
7. Postpartum care of the mother and the newborn: a practical guide 1998, World Health Organization, World Health Organization, Geneva, (WHO/RHT/MSM/98.3).
8. York P. Dosage forms of medicines for children. Report of informal expert meeting: World Health Organization December 2008, World Health Organization, Geneva, Switzerland.
9. Mansour H.M., Rhee Y.S., Park C.W., De Luca P.P. Lipid nanoparticulate drug delivery and nanomedicine. Lipids in Nanotechnology 2011, 221-268. American Oil Chemists Society Press, Chicago, Ill. A. Moghis (Ed.).
10. Löbenberg R., Amidon G.L. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm 2000, 50:3-12.
11. Custodio J.M., Wu C.Y., Benet L.Z. Predicting drug disposition absorption/elimination and the role of food on drug absorption. Adv Drug Deliv Rev 2008, 60:717-733.
12. O'Hagan D.T., Rappuoli R. Novel approaches to pediatric vaccine delivery. Adv Drug Deliv Rev 2006, 58:29-51.
13. Raz I., Weiss R., Yegorchikov Y., et al. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Clin Ther 2009, 31:980-987.
14. Garland M.J., Migalska K., Mahmood T.M., et al. Microneedle arrays as medical devices for enhanced transdermal drug delivery. Expert Rev Med Devices 2011, 8:459-482.
15. Gaudana R., Ananthula H.K., Parenky A., Mitra A.K. Ocular drug delivery. AAPS J 2010, 12:348-360.
16. Hård A.L., Hellström A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment - a review. Acta Paediatr 2011, 100:1523-1527.
17. Mintz-Hittner H.A., Kennedy K.A., Chuang A.Z. BEAT-ROP Cooperative Group: efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011, 364:603-615.
18. Lowenthal D., Kattan M. Facemasks versus mouthpieces for aerosol treatment of asthmatic children. Pediatr Pulmonol 1992, 14:192.
19. Mellon M., Leflein J., Walton-Bowen K., et al. Comparable efficacy of administration with facemask or mouthpiece of nebulized budesonide inhalation suspension for infants and young children with persistent asthma. Am J Respir Crit Care Med 2000, 162:593-598.
20. Jaafar-Maalej C., Elaissari A., Fessi H. Lipid-based carriers: manufacturing and applications for pulmonary route. Expert Opin Drug Deliv 2012, 9:1111-1127.
21. Beck-Broichsitter M., Kleimann P., Schmehl T., et al. Impact of lyoprotectants for the stabilization of biode-gradable nanoparticles on the performance of air-jet, ultrasonic, and vibrating-mesh nebulizers. Eur J Pharm Biopharm 2012 Jul 20, [Epub ahead of print].
22. Menjoge A.R., Kannan R.M., Tomalia D.A. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today 2010, 15:171-185.
23. Kannan S., Dai H., Navath R.S., et al. Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci Transl Med 2012, 4:130-146.
24. Timko B.P., Dvir T., Kohane D.S. Remotely triggerable drug delivery systems. Adv Mater 2010, 22:4925-4943.
25. Anand V., Kataria M., Kukkar V., et al. The latest trends in the taste assessment of pharmaceuticals. Drug Discov Today 2007, 12:257-265.
26. Talavera K., Yasumatsu K., Yoshida R., et al. The taste transduction channel TRPM5 is a locus for bitter-sweet taste interactions. FASEB J 2008, 22:1343-1355.
27. Lipchock S.V., Reed D.R., Mennella J.A. Relationship between bitter-taste receptor genotype and solid medication formulation usage among young children: a retrospective analysis. Clin Ther 2012, 34:728-733.
28. Choonara I., Bonati M. European legislation to improve medicines for children. Paediatr Perinat Drug Ther 2007, 8:2-3.
29. Thomson S.A., Tuleu C., Wong I.C., et al. Minitablets: new modality to deliver medicines to preschool-aged children. Pediatrics 2009, 123:e235-e238.
30. Stoltenberg I., Breitkreutz J. Orally disintegrating mini-tablets (ODMTs)-a novel solid oral dosage form for paediatric use. Eur J Pharm Biopharm 2011, 78:462-469.